Lacrimal Sac Tumors: A Single-institution Experience, Including New Insights

TAKAHIRO WAKASAKI^{1,2}, RYUJI YASUMATSU³, MIKA TANABE⁴, HIROSHI YOSHIKAWA⁴, RINA JIROMARU¹, KAZUKI HASHIMOTO¹, MIOKO MATSUO¹, AKIKO FUJIMURA^{1,2} and TAKASHI NAKAGAWA¹

¹Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;

²Department of Otorhinolaryngology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan;

³Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine,

Kindai University, Osaka, Japan;

⁴Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Abstract. Background/Aim: Lacrimal sac tumors are rare tumor types, with a long time interval from disease onset to diagnosis. We aimed to investigate the characteristics and outcomes of patients with lacrimal sac tumors. Patients and Methods: The medical records of 25 patients with lacrimal sac tumors initially treated at the Kyushu university hospital from January 1996 to July 2020 were reviewed. Results: Our analysis included 3 epithelial benign tumors (12.0%) and 22 malignant (88.0%) tumors (squamous cell carcinoma, n=6; adenoid cystic carcinoma, n=2; sebaceous adenocarcinoma, n=2; mucoepidermoid carcinoma, n=1; malignant lymphoma, n=10). The average time from symptom onset to diagnosis was 14.7 months (median=8 months; range=1-96 months). The analysis of patients revealed that lacrimal sac mass (22/25, 88.0%) was the most frequent symptom and a possible tumor marker. Most epithelial benign (n=3) and malignant epithelial (n=12) tumors were treated surgically (14/15), 93.3%). One malignant case was treated with heavy ion beam therapy. Eight patients were treated with postoperative (chemo)radiation therapy because of positive surgical margins (including one unanalyzed case). Local control was ultimately achieved in all but one case. The patient survived for 24 months with immune checkpoint inhibitors and

Correspondence to: Takahiro Wakasaki, MD, Ph.D., Department of Otorhinolaryngology, Japanese Red Cross Fukuoka Hospital, Fukuoka 815-8555, Japan. E-mail: hayatenn@gmail.com

Key Words: Dacryocystitis, dacryocystorhinostomy, lacrimal sac tumors, lacrimal sac carcinoma.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

subsequent chemotherapy for local and metastatic recurrence. Conclusion: We report our experience in the diagnosis and treatment of lacrimal sac tumors and analyze the clinical trends in cases involving these tumors. Postoperative radiotherapy and pharmacotherapy, including immune checkpoint inhibitors, may be useful for recurrent cases.

The lacrimal duct is composed of a lacrimal punctum, lacrimal duct, lacrimal sac, and nasolacrimal duct. While tumor development is rare (1), lacrimal sac tumors are the most common lacrimal duct tumor (2-5). There are few coherent reports, with most being case reports. Lacrimal sac tumors are usually malignant (55%-100%), (2-4, 6) and early detection is desirable. Symptoms are unlikely to occur unless the tumor is enlarged. Tumor detection often occurs when there is obstruction of the lacrimal canal, such as tears, or lacrimal sac symptoms, such as reddening and pain in the skin. These non-specific clinical manifestations can cause misdiagnosis of lacrimal sac tumor as dacryocystitis, and patients continue to receive treatment for dacryocystitis, such as nasolacrimal duct cleaning, for a prolonged period of time (2, 4).

Because of the various histological systems of lacrimal sac tumors, treatment should be based on histological type and degree of pathologic progression (3). Papillomas are the most common epithelial tumor (36%) and tend to recur (10%-40%), particularly inverted papilloma, due to its high rate of malignant transformation. Among malignant tumors, squamous cell carcinomas occur most frequently. Other malignancies include adenocarcinomas, mucoepidermoid carcinomas, adenoid cystic carcinoma, and basal cell carcinoma. Despite treatment, however, rates of carcinoma recurrence and mortality are approximately 50% and approximately 37%-100%, respectively, with mortality rates increasing with recurrence. Local recurrence occurs because of inadequate resection margins due to adjacent anatomical structures. Multidisciplinary treatment,

such as radiotherapy, is most effective. If the pathology requires resection, depending on the extent of tumor progression, adjacent structures, such as the eyeball, nasal bone, maxillary bone, or sinus, may have to be removed (1).

Advanced medical treatments such as heavy particle ion beam therapy and immune checkpoint inhibitors (ICIs) are used to treat malignancies. We herein report our experience in diagnosing and treating lacrimal sac tumors and analyze the clinical trends in lacrimal sac tumor cases in our hospital. We aimed to investigate the characteristics and outcomes of patients with lacrimal sac tumors.

Patients and Methods

Patients. Out of 547 cases of orbital-related tumors and lacrimal duct tumors treated at the Kyushu University Hospital from January 1996 to December 2019, 25 were diagnosed as lacrimal sac tumors. The inclusion criteria were as follows: 1) patients with lacrimal sac tumor treated at Kyushu University Hospital from January 1996 to December 2019; and 2) age ≥ 20 years. Patients who were <20 years of age were excluded from the study. This was a retrospective study with clinical data collected from medical records. All of these patients with lacrimal sac tumors were diagnosed by our ophthalmologist and head and neck surgeon based on the examination, computed tomography or magnetic resonance imaging findings, where the primary locus of the tumor was located in the lacrimal sac. Lacrimal sac tumors were diagnosed when the tumors were most predominantly located in the lacrimal sac region of the lacrimal duct. Pathological diagnoses were made by a pathologist in our hospital. This retrospective study was approved by the Institutional review board of our hospital (reference number: 29-43) and was conducted in accordance with the principles of the Declaration of Helsinki.

Results

Patient information is summarized in Table I. There were no marked differences in the rate of males and females (14 males, 11 females). The average age was 58.7 (32-88) years for all cases, 51.3 (46-60) years old for benign epithelial tumors, 61.6 (45-87) years old for epithelial malignancies, and 57.5 (32-88) years old for non-epithelial malignancies.

Pathological results are summarized in Table II. Malignancies accounted for 23 (88.0%) cases compared to 3 benign (12.0%) cases. All benign cases were papilloma. There were 12 epithelial malignancies (48.0%) and 10 nonepithelial malignancies (40.0%). Malignant epithelial tumors included six squamous cell carcinomas (SCCs) of undetermined papilloma origin and various cancers. All nonepithelial malignancies were lymphomas.

Detailed data for the 25 primary patients were obtained from medical records (Table II). In 22 of the 25 cases (88.0%), the most common subjective symptom at diagnosis was a mass in the lacrimal sac (Table III). Twenty-one patients (84.0%) presented with lacrimation. One of the three patients presenting with bloody lacrimation was diagnosed with benign epithelial Table I. Pathological diagnosis of lacrimal sac tumor patients included in the study (n=25).

	n	%	Median age (range)
Benign	3	12.0	48.0 years (46-60)
Inverted papilloma	1	4.0	-
Exophytic papilloma	2	8.0	
Malignant	22	88.0	61.0 years (34-88)
Epithelial disease	12	48.0	59.5 years (45-87)
Squamous cell carcinoma	6	24.0	• • •
Adenoid cystic carcinoma,	3	12.0	
cribriform type			
Sebaceous gland carcinoma	2	8.0	
Mucoepidermoid carcinoma,	1	4.0	
low grade			
Lymphoproliferative disease	10	40.0	62.5 years (32-88)
DLBC lymphoma	4	16.0	• • •
MALT lymphoma	4	16.0	
Burkitt lymphoma	1	4.0	
KT cell lymphoma	1	4.0	

DLBCL, Diffuse large B-cell lymphoma; MALT lymphoma, mucosaassociated lymphoid tissue lymphoma; NKT cell lymphoma, natural killer cell lymphoma.

tumor. Fourteen patients (56.0%) had a history of chronic dacryocystitis, and 5 had undergone dacryocystorhinostomy (DCR). Diagnoses were made by an external incision biopsy (n=20, 80.0%) or a transnasal biopsy (n=5, 20.0%). Only one case was diagnosed by a biopsy during DCR. The average time from symptom onset to diagnosis was 17.2 months (median=8 months, range=1-96 months).

Treatment depended on the pathological diagnosis (Table IV). The initial treatment of benign (n=3) and epithelial malignancies (n=12) was surgery (14/15, 93.3%). Of the 11 patients with epithelial malignancies who underwent surgery, 8 were treated with postoperative (chemo) radiotherapy (Table V). Patients with sebaceous adenocarcinoma who did not receive surgical treatment chose heavy ion beam therapy but developed recurrence of neck lymph node metastasis and therefore underwent postoperative chemoradiation following neck dissection. Regarding the operated epithelial tumors, 11 of the 14 patients (78.6%) underwent free-flap mandibular reconstructions following resection, and 8 (57.1%) underwent simultaneous reconstruction with nonvascularized bone grafts with free bone grafting. Extended total maxillary resection with eveball resection was performed in two squamous cell carcinoma patients and one sebaceous adenocarcinoma patient. Only two patients with SCC underwent neck dissection as the initial treatment, and one patient pathologically represented with neck lymph node metastases (submental and submandibular lymph node, no extranodal extension).

Patient follow-up lasted until death or until the cut-off date (December 31, 2021). The median duration of follow-up from the diagnosis for epithelial malignancies was 37.5 (13-176)

n=25)
study (
the 2
in
luded
incl
atients
of p
souses
dia
gical
olc
pathe
and
ristics
ıracte
chai
al
clinic
. Detailed
Ξ
Table

QuertyMonoperformantMeanousLacti- actionBiology lacti- instrinalMass of mation47MEprithelialBenignTransmasalExophytic+++47MEprithelialBenignTransmasalExophytic+-++48MEprithelialBenignTransmasalExophytic+++45MEprithelialBenignTransmasalExophytic+53MEprithelialBenignIncisionalInverted53MEprithelialMalignantIncisionalInverted53MEprithelialMalignantIncisionalIncisionalACC,++++++53MEprithelialMalignantIncisionalNCC,+++++57MEprithelialMalignantIncisionalNCC,++ <td< th=""><th>MutuputMethodDagroupLatricBloodyMass ofRuberfactionPainDologianReingnTransmashExophylic++++ColuraBeringnTransmashExophylic+++++ColuraBeringnTransmashExophylic++++++BeringnTransmashExophylic+++++++MalignantIncisionalExophylic+<t< th=""><th>Sex</th><th>Epithelial or</th><th>Benign or</th><th>Diagnostic</th><th>Histopathological</th><th></th><th></th><th>Symp</th><th>Symptoms</th><th></th><th></th><th>Treatment</th><th>DCR</th><th>Period from</th></t<></th></td<>	MutuputMethodDagroupLatricBloodyMass ofRuberfactionPainDologianReingnTransmashExophylic++++ColuraBeringnTransmashExophylic+++++ColuraBeringnTransmashExophylic++++++BeringnTransmashExophylic+++++++MalignantIncisionalExophylic+ <t< th=""><th>Sex</th><th>Epithelial or</th><th>Benign or</th><th>Diagnostic</th><th>Histopathological</th><th></th><th></th><th>Symp</th><th>Symptoms</th><th></th><th></th><th>Treatment</th><th>DCR</th><th>Period from</th></t<>	Sex	Epithelial or	Benign or	Diagnostic	Histopathological			Symp	Symptoms			Treatment	DCR	Period from
 47 M Epithelial Benign Transmasal Exophytic + 60 M Epithelial Benign Transmasal Exophytic + 48 M Epithelial Benign Incisional Inverted - 45 M Epithelial Benign Incisional Inverted - 53 M Epithelial Banign Incisional Inverted - 53 M Epithelial Malignant Incisional ACC, + 54 F Epithelial Malignant Incisional ACC, + 55 F Epithelial Malignant Incisional ACC, + 57 F Epithelial Malignant Incisional ACC, + 58 F Epithelial Malignant Incisional ACC, + 59 M Epithelial Malignant Incisional ACC, + 51 F Epithelial Malignant Incisional ACC, + 52 M Epithelial Malignant Incisional ACC, + 53 M Epithelial Malignant Incisional ACC, + 54 F Epithelial Malignant Incisional ACC, + 57 M Epithelial Malignant Incisional SCC, + 58 M Epithelial Malignant Incisional SCC, + 59 M Epithelial Malignant Incisional SCC, + 51 M Non-opithelial Malignant Incisional Scocecous + 54 M Non-opithelial Malignant Incisional Schercous 54 M Non-opithelial Malignant Incisional Butkitt 55 M Non-opithelial Malignant Incisional Butkitt 56 F Epithelial Malignant Incisional Butkitt 57 M Epithelial Malignant Incisional Butkitt 58 M Non-opithelial Malignant Incisional Butkitt 59 M Non-opithelial Malignant Incisional Butkitt 50 M Non-opithelial Malignant Incisional Butkitt 51 M Non-opithelial Malignant Incisional Butkitt 53 M Non-opithelial Malignant Incisional Incisional Incisional Incisional Incisional Incisional Incisional Incisional Incisiona	BerignTransmalExophytic+-+BerignTransmasiExophytic+BerignTransmasiExophytic++++++BerignInsistonalInvertedBuiltyInsistonalInvertedMalignantInsistonalACC+MalignantInsistonalACC++-++++MalignantInsistonalSubyteMalignantInsistonalNobyte-++++++++-MalignantInsistonalNobyteNobyte-+++++++-MalignantInsistonalNobyteNobyteNobyte+++ <th></th> <th>non-epithelial tumor</th> <th>Malignant</th> <th>Method</th> <th>Diagnosis</th> <th>Lacri- mation</th> <th>Bloody lacri- mation</th> <th></th> <th>Rubefaction of medial canthus</th> <th>Pain</th> <th>Diplopia/ Ocular motility disorder</th> <th>nistory or dacryocystitis</th> <th></th> <th>appearance of chief complaint to diagnosis (months)</th>		non-epithelial tumor	Malignant	Method	Diagnosis	Lacri- mation	Bloody lacri- mation		Rubefaction of medial canthus	Pain	Diplopia/ Ocular motility disorder	nistory or dacryocystitis		appearance of chief complaint to diagnosis (months)
60 M Epithelial Benign biopsy papilioma + 48 M Epithelial Benign biopsy papilioma + + 45 M Epithelial Benign frictional biopsy papilioma + + 53 M Epithelial Malgnant Incisional invected - - 57 F Epithelial Malgnant Incisional ACC, + + - 57 F Epithelial Malgnant Incisional ACC, + + - 58 F Epithelial Malgnant Incisional ACC, + + + 57 M Epithelial Malgnant Incisional SCC, + + + 57 M Epithelial Malgnant Incisional SCC, + + + + + + + + + + + <td>BenignDiopsy bopypopilloma bopy<</br></br></br></br></br></br></br></br></br></br></br></br></br></td> <td>M</td> <td>Epithelial</td> <td>Benign</td> <td>Transnasal</td> <td>Exophytic</td> <td>+</td> <td> 1</td> <td>+</td> <td>I</td> <td>1</td> <td>I</td> <td>+</td> <td>+</td> <td>12</td>	BenignDiopsy bopypopilloma 	M	Epithelial	Benign	Transnasal	Exophytic	+	1	+	I	1	I	+	+	12
 M Epithelial Benign Incisional Inverted - comproper tumor partitional attractional inverted - comproper tumor tumor biopsy papillona - comproper tumor unnor biopsy papillona - comproper - compreserving - comproper		Ν	tumor Enithelial	Ranian	biopsy Transnasal	papilloma Eventuatio	4	4	4	4	I	I	4	I	18
 48 M Epithelial Benign Incisional Inverted - unnor unnor biopsy applilona - unnor unnor unnor biopsy applilona - a subtype - a unnor biopsy applilona - a subtype - a unnor biopsy application - a subtype - a unnor biopsy application - a subtype - a unnor biopsy application - a subtype - a nunor biopsy application - a nunor - a nunor - biopsy application - a nunor - a nunor - a biopsy application - a nunor - a nun	BerignIncisional holpsyInvertedMalignanthorskycribriform ACC_1 +Malignanthorskycribriform ACC_1 +Malignanthorskycribriform ACC_1 +-+++++Malignanthorskycribriform ACC_1 +++++++Malignanthorskysubbyssubbys ACC_1 +++++++-Malignanthorsky $B(N/A)$ +++++++++++Malignanthorsky $B(N/A)$ +++++++++++Malignanthorsky $B(N/A)$ +++ <td></td> <td>tumor</td> <td>nom61</td> <td>biopsy</td> <td>papilloma</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td></td> <td></td> <td>-</td> <td></td> <td>2</td>		tumor	nom61	biopsy	papilloma	-	-	-	-			-		2
 45 M Epithelial Malignant Incisional ACC, +	MalignantIncisional biopsyAprilloma antrygeAprilloma teribriformAprilloma teribriformAprilloma teribriformAprilloma teribriformAprilMalignantIncisional 	Μ	Epithelial	Benign	Incisional	Inverted	I	I	I	I	I	I	I	I	1
 A. D. Epithelial Malgnant Incisional historya subtype tumor tumor biopsy cribriform aubtype tumor tumor biopsy cribriform biopsy cribriform aubtype tumor biopsy cribriform aubtype subtype tumor biopsy cribriform biopsy cribriform aubtype tumor biopsy cribriform biopsy cribriform aubtype tumor biopsy pl6 (N/A) + + + + + + + + + + + + + + + + + + +	MalgmanIncisional hoipoy $TACC$ $+$ $ -$		tumor E-::-1:-1	1- J.	biopsy	papilloma									č
 53 M Epithelial Malignant Incisional ACC, + 57 F Epithelial Malignant Iransnasal ACC, + 57 F Epithelial Malignant Transnasal ACC, + 58 F Epithelial Malignant Incisional NCC, + 58 F Epithelial Malignant Incisional SCC, + 57 M Epithelial Malignant Incisional NCC, + 58 T Epithelial Malignant Incisional NCC, + 57 M Epithelial Malignant Incisional NCC, + 57 M Epithelial Malignant Incisional SCC, + 57 M Epithelial Malignant Incisional NCC, + 57 M Epithelial Malignant Incisional SCC, + 57 M Epithelial Malignant Incisional SCC, + 57 M Epithelial Malignant Incisional SCC, + 58 M Epithelial Malignant Incisional SCC, + 59 M Epithelial Malignant Incisional SCC, + 50 M Epithelial Malignant Incisional SCC, + 51 M Epithelial Malignant Incisional SCC, + 53 M Epithelial Malignant Incisional SCC, + 54 M Epithelial Malignant Incisional SCC, + 55 M Epithelial Malignant Incisional SCC, + 56 ACC, + 57 M Epithelial Malignant Incisional SCC, + 58 ACC, + 59 M Epithelial Malignant Incisional SCC, + 50 M Epithelial Malignant Incisional SCC, + 55 M Epithelial Malignant Incisional SCC, + 56 ACC, + 57 M Epithelial Malignant Incisional Nocepidermoid + 58 Augure Augure	MaignantIncisional biopysuoype cribriform++++++MaignantTransnasal biopycribriform++++++++++MaignantTransnasal 	Μ	Epitnelial	Malignant	Incisional biopsy	AUC, cribriform	+	I	I	I	I	I	+	I	24
 F Epithelial Malignant Transnasal cribriform F Epithelial Malignant Transnasal aubtype F Epithelial Malignant Transnasal cribriform F Epithelial Malignant Incisional SCC, + + + M Epithelial Malignant Incisional SCC, + + + + M Epithelial Malignant Incisional SCC, + + + + M Epithelial Malignant Incisional SCC, + + + + M Epithelial Malignant Incisional SCC, + + + + M Epithelial Malignant Incisional SCC, + + + + M Epithelial Malignant Incisional SCC, + + + + M Epithelial Malignant Incisional SCC, + + + + M Epithelial Malignant Incisional SCC, + + + + M Non-epithelial Malignant Incisional Nuccepidermoid + + + M Non-epithelial Malignant Incisional DLBCL + + + M Non-epithelial Malignant Incisional DLBCL + + + + 	biopsycribritornMalgnantTransnastsubtypebiopsybiopsysubtypebiopsycribritornsubtypeMalgnantIncisionalSCC,++biopsypl6 (N/A)+++MalgnantIncisionalSCC,+++biopsypl6 (N/A)++++MalgnantIncisionalSCC,+++biopsypl6 (N/A)++++MalgnantIncisionalSCC,+++biopsypl6 (N/A)++++MalgnantIncisionalSCC,+++biopsypl6 (N/A)++++MalgnantIncisionalSCC,+++MalgnantIncisionalSCC,+++MalgnantIncisionalScbaccous+-+MalgnantIncisionalScbaccous+-++MalgnantIncisionalScbaccous+-++MalgnantIncisionalScbaccous+++MalgnantIncisionalScbaccous++++MalgnantIncisionalScbaccous+++++MalgnantIncisionalScbaccous+++++Malgn	Μ	Epithelial	Malignant	Incisional	subtype ACC,	+	I	+	+	+	Ι	+	I	9
 57 F Epithelial Malignant Transnasal auotype 64 F Epithelial Malignant Transnasal biopsy cribriform 58 F Epithelial Malignant Incisional SCC, + + + tumor 58 F Epithelial Malignant Incisional SCC, + + + tumor 57 M Epithelial Malignant Incisional SCC, + + - 57 M Epithelial Malignant Incisional SCC, + + - 57 M Epithelial Malignant Incisional SCC, + + - 57 M Epithelial Malignant Incisional SCC, + + - 57 M Epithelial Malignant Incisional SCC, + + - 58 M Epithelial Malignant Incisional SCC, + + - 59 M Epithelial Malignant Incisional SCC, + + - 50 M Epithelial Malignant Incisional SCC, + + - 53 M Epithelial Malignant Incisional SCC, + + - 54 M Non-epithelial Malignant Incisional Scbaceous 55 M Epithelial Malignant Incisional SCC, + + - 56 F Epithelial Malignant Incisional SCC, + + - 57 M Epithelial Malignant Incisional SCC, + + - 58 M Epithelial Malignant Incisional SCC, + + - 59 M Epithelial Malignant Incisional Scbaceous 51 M Non-epithelial Malignant Incisional Scbaceous 53 M Non-epithelial Malignant Incisional Scbaceous 54 M Non-epithelial Malignant Incisional DLBCL + + - 55 M Epithelial Malignant Incisional DLBCL + + - 	MalignantTransnaal biopsyworype subrype++++-MalignantIncisional biopsysubrype subrype+++++++MalignantIncisional biopsySCC,++++++++MalignantIncisional biopsySCC,+++++++++MalignantIncisional biopsySCC,+++++++++MalignantIncisional biopsySCC,++++++++++MalignantIncisional biopsySCC,++		tumor)	biopsy	cribriform									
iumorbiopsycribriform subtype64FEpithelialMalignantIncisionalSCC,+58FEpithelialMalignantIncisionalSCC,+58FEpithelialMalignantIncisionalSCC,+57MEpithelialMalignantIncisionalSCC,+70MEpithelialMalignantIncisionalSCC,+70MEpithelialMalignantIncisionalSCC,+70MEpithelialMalignantIncisionalSCC,+70MEpithelialMalignantIncisionalSCC,+70MEpithelialMalignantIncisionalSCC,+70MEpithelialMalignantIncisionalSCC,+70MEpithelialMalignantIncisionalSCC,+76FEpithelialMalignantIncisionalSCC,+76FEpithelialMalignantIncisionalSCC,+77MEpithelialMalignantIncisionalSCC,+78MEpithelialMalignantIncisionalSCC,+78MEpithelialMalignantIncisionalSCC,+78MEpithelialMalignantIncisionalSCC,+79FEpithelialMalignantIncisionalSCC,+ <td< td=""><td>Nalignantbiopsy noisonalcribriform subtypeMalignantIncisionalSCC,+++++biopsy$pl6 (N/A)$++++++++MalignantIncisionalSCC,+++++++++MalignantIncisionalSCC,++++++++++MalignantIncisionalSCC,++++++++++MalignantIncisionalSCC,+++++++++++MalignantIncisionalSCC,++-++<td>Ц</td><td>Epithelial</td><td>Malignant</td><td>Transnasal</td><td>subtype ACC,</td><td>+</td><td>I</td><td>+</td><td>I</td><td>I</td><td>Ι</td><td>+</td><td>I</td><td>18</td></td></td<>	Nalignantbiopsy noisonalcribriform subtypeMalignantIncisionalSCC,+++++biopsy $pl6 (N/A)$ ++++++++MalignantIncisionalSCC,+++++++++MalignantIncisionalSCC,++++++++++MalignantIncisionalSCC,++++++++++MalignantIncisionalSCC,+++++++++++MalignantIncisionalSCC,++-++ <td>Ц</td> <td>Epithelial</td> <td>Malignant</td> <td>Transnasal</td> <td>subtype ACC,</td> <td>+</td> <td>I</td> <td>+</td> <td>I</td> <td>I</td> <td>Ι</td> <td>+</td> <td>I</td> <td>18</td>	Ц	Epithelial	Malignant	Transnasal	subtype ACC,	+	I	+	I	I	Ι	+	I	18
 64 F Epithelial Malignant Incisional SCC, + tumor 58 F Epithelial Malignant Incisional SCC, + tumor 51 F Epithelial Malignant Incisional SCC, + tumor 57 M Epithelial Malignant Incisional SCC, + tumor 70 M Epithelial Malignant Incisional SCC, + tumor 70 M Epithelial Malignant Incisional SCC, + tumor 70 M Epithelial Malignant Incisional SCC, + tumor 71 M Epithelial Malignant Incisional SCC, + tumor 72 M Epithelial Malignant Incisional SCC, + tumor 73 M Epithelial Malignant Incisional SCC, + tumor 74 Epithelial Malignant Incisional SCC, + tumor 75 M Epithelial Malignant Incisional SCC, + tumor 76 F Epithelial Malignant Incisional SCC, + tumor 77 M Epithelial Malignant Incisional SCC, + tumor 78 M Epithelial Malignant Incisional ScCC, + tumor 79 M Epithelial Malignant Incisional ScCC, + tumor 70 M Epithelial Malignant Incisional ScCC, + tumor 71 M Epithelial Malignant Incisional ScCC, + tumor 73 M Non-epithelial Malignant Incisional Schaceous 74 M Non-epithelial Malignant Incisional Schaceous 75 M Non-epithelial Malignant Incisional Schaceous 76 F Non-epithelial Malignant Incisional Schaceous 77 M Epithelial Malignant Incisional Schaceous 78 M Non-epithelial Malignant Incisional Schaceous 79 M Non-epithelial Malignant Incisional Nuccepidermoid 70 M Scocepidermoid 71 H Non-epithelial Malignant Incisional Nuccepidermoid 73 M Non-epithelial Malignant Incisional Nuccepidermoid 74 M Non-epithelial Malignant Incisional Nuccepidermoid 75 H M Non-epithelial Malignant Incisional Nuccepidermoid 76 H Non-epithelial Malignant Incisional Nuccepidermoid 77 H H Non-epithelial Malignant Incisional Nuccepidermoid 	MalignantIncisional biopsySCC, biopsy $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $-$ MalignantIncisional biopsySCC, 		tumor)	biopsy	cribriform									
 F Epithelial Malignant Incisional SCC, + tumor tumor F Epithelial Malignant Incisional SCC, + tumor F Epithelial Malignant Incisional SCC, + tumor F Epithelial Malignant Incisional SCC, + tumor Malignant Incisional Scocecous + tumor Malignant Incisional Sebaceous + tumor Mon-epithelial Malignant Incisional Sebaceous Mon-epithelial Malignant Incisional DLBCL + tumor 	MalignantIncisional biopsy $PI6$ (NA) SCC, $+$ $+$ $+$ $+$ $ -$ MalignantIncisional biopsy SCC , $+$ $+$ $+$ $ -$ MalignantIncisional biopsy SCC , $+$ $+$ $+$ $ -$ MalignantIncisional biopsy SCC , $+$ $ +$ $ -$ MalignantIncisional biopsy SCC , $+$ $ +$ $ -$ MalignantIncisional biopsy SCC , $+$ $ +$ $ +$ $-$ MalignantIncisional biopsy SCC , $+$ $ +$ $ +$ $ +$ $-$ MalignantIncisional biopsy SCC , $+$ $ +$ $ +$ $ +$ $-$ MalignantIncisional biopsy $Sebaceousbiopsy+ + -MalignantIncisionalbiopsySebaceousbiopsy+ -$	ŢŢ	Enithelial	Malionant	Incisional	subtype	+	+	+	+	+	I	+	+	L
58FEpithelialMalignantIncisional61FEpithelialMalignantIncisional57MEpithelialMalignantIncisional70MEpithelialMalignantIncisional70MEpithelialMalignantIncisional70MEpithelialMalignantIncisional70MEpithelialMalignantIncisional63MEpithelialMalignantIncisional76FEpithelialMalignantIncisional77FEpithelialMalignantIncisional78MEpithelialMalignantIncisional79TRalignantIncisional71FEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MNon-epithelialMalignantIncisional87MNon-epithelialMalignantIncisional87MNon-epithelialMalignantIncisional83MNon-epithelialMalignantIncisional84MNon-epithelialMalignantIncisional84MNon-epithelialMalignantIncisional84MNon-epithelialMalignantIncisional84MNon-epithelial <td< td=""><td>MalignantIncisionalSCC,+-+-+MalignantlicisionalSCC,++++++MalignantlicisionalSCC,+++++++-++-MalignantlicisionalSCC,++-++++-++-MalignantlicisionalSCC,+-++++++++MalignantlicisionalSCC,++-+++++++MalignantlicisionalSCC,++-++</td></td<> <td>(</td> <td>tumor</td> <td>0</td> <td>biopsy</td> <td>p16 (N/A)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	MalignantIncisionalSCC,+-+-+MalignantlicisionalSCC,++++++MalignantlicisionalSCC,+++++++-++-MalignantlicisionalSCC,++-++++-++-MalignantlicisionalSCC,+-++++++++MalignantlicisionalSCC,++-+++++++MalignantlicisionalSCC,++-++	(tumor	0	biopsy	p16 (N/A)									
61Ftumorbiopsy57MEpithelialMalignantIncisional57MEpithelialMalignantIncisional70MEpithelialMalignantIncisional48MEpithelialMalignantIncisional63MEpithelialMalignantIncisional76FEpithelialMalignantIncisional78MEpithelialMalignantIncisional79KEpithelialMalignantIncisional70FEpithelialMalignantIncisional76FEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MNon-epithelialMalignantIncisional87MNon-epithelialMalignantIncisional87MNon-epithelialMalignantIncisional87MNon-epithelialMalignantIncisional88MNon-epithelialMalignantIncisional89MNon-epithelialMalignantIncisional84MNon-epithelialMalignantIncisional84MNon-epithelialMalignantIncisional84MNon-epithelialMal	Malignantbiopsy noisysyp16 (N(A) SCC,+++++-MalignantIncisional biopsySCC,+++++-++-MalignantIncisional biopsySCC,++-++++-++-++++++++-+++ <t< td=""><td>Ц</td><td>Epithelial</td><td>Malignant</td><td>Incisional</td><td>SCC,</td><td>+</td><td>I</td><td>+</td><td>I</td><td>Ι</td><td>Ι</td><td>I</td><td>I</td><td>48</td></t<>	Ц	Epithelial	Malignant	Incisional	SCC,	+	I	+	I	Ι	Ι	I	I	48
 r r principal Malignant Incisional tumor Malignant Incisional tumor Malignant Incisional biopsy tumor Malignant Incisional biopsy tumor Malignant Incisional tumor Malignant Incisional biopsy tumor Malignant Incisional biopsy tumor Malignant Incisional tumor F Epithelial Malignant Incisional tumor Malignant Incisional tumor 	MatignantIncisional biopsy $D(C_{N}(A)$ $+$ <	Ľ	tumor ExitEntiol	Mol: mont	biopsy	p16 (N/A)			-		-				20
57MEpithelialMalignantIncisional70MEpithelialMalignantIncisional48MEpithelialMalignantIncisional63MEpithelialMalignantIncisional76FEpithelialMalignantIncisional78MEpithelialMalignantIncisional78FEpithelialMalignantIncisional79FEpithelialMalignantIncisional76FEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantIncisional83ANon-epithelialMalignantIncisional84MNon-epithelialMalignantIncisional84MNon-epithelialMalignantIncisional84MNon-epithelialMalignantIncisional84MNon-epithelialMalignantIncisional84MNon-epithelialMalignantIncisional85MNon-epithelialMalignantIncisional86MNon-epithelialMalignantIncisional87MNon-epithelialMalignantIncisional	MalignantIncisional biopsyFCC, biopsy+-+MalignantIncisional biopsySCC, 	4	timor	INTALLIBILIATIL	hionsv	5CC, n16 (N/A)	F	F	F	I	F	I	I	I	00
70MEpithelialMalignantbiopsy48MEpithelialMalignantIncisional48MEpithelialMalignantIncisional63MEpithelialMalignantIncisional76FEpithelialMalignantIncisional78MEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantIncisional83MNon-epithelialMalignantIncisional94tumorbiopsybiopsy34MNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional10058ytumorbiopsybiopsy34MNon-epithelialMalignantIncisional10058ytumorbiopsybiopsy	Malignantbiopsy biopsyp16 negative biopsy++++++MalignantIncisional biopsySCC, 	Μ	Epithelial	Malignant	Incisional	SCC,	+	I	+	I	I	I	I	I	48
70 M Epithelial Malignant Incisional 48 M Epithelial Malignant Incisional 63 M Epithelial Malignant Incisional 76 F Epithelial Malignant Incisional 78 M Epithelial Malignant Incisional 76 F Epithelial Malignant Incisional 76 F Bpithelial Malignant Incisional 87 M Epithelial Malignant Incisional 87 M Epithelial Malignant Incisional 87 M Epithelial Malignant Incisional 83 M Epithelial Malignant Incisional 94 Non-epithelial Malignant Incisional 34 M Non-epithelial Malignant Incisional 34 M Non-epithelial Malignant Incisional 94 N Non-epithelial Malignant Incisional 94 M Non-epithelial Malignant Incisional	Malignant Incisional SCC, + - + + - + + - + + - + + - + + - + + - + + - + + - + + - + + + - + + + - + + + - + + + - + + + - + + + + - +	2	tumor		biopsy	p16 negative									
48MEpithelial tumorMalignantIncisional biopsy63MEpithelialMalignantIncisional biopsy76FEpithelialMalignantIncisional biopsy87MEpithelialMalignantIncisional biopsy87MEpithelialMalignantIncisional biopsy87MEpithelialMalignantIncisional biopsy61FNon-epithelialMalignantIncisional during DCR34MNon-epithelialMalignantIncisional biopsy34MNon-epithelialMalignantIncisional biopsy34MNon-epithelialMalignantIncisional biopsy34MNon-epithelialMalignantIncisional biopsy34MNon-epithelialMalignantIncisional biopsy	MalignantIncisionalSSC, the second second+-+++-+++<	Μ	Epithelial	Malignant	Incisional	SCC, n16 nositive	+	I	+	+	I	+	I	I	4
63Mtumorbiopsy63MEpithelialMalignantIncisional76FEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MNon-epithelialMalignantIncisional91FNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional1tumortumorbiopsy34MNon-epithelialMalignantIncisional1tumortumorbiopsy	biopsyp16 positiveMalignantIncisionalSebaceous+-++biopsygland carcinoma+-+++MalignantIncisionalSebaceous+-+++MalignantIncisionalSebaceous+-++++MalignantTransnasalMucoepidermoid+MalignantIncisionalBurkitt+MalignantIncisionalDLBCL+-+MalignantIncisionalDLBCL+-+MalignantIncisionalDLBCL+-++MalignantIncisionalDLBCL+-++MalignantIncisionalDLBCL++MalignantIncisionalDLBCL+++++++MalignantIncisionalDLBCLMalignantIncisionalDLBCL+++++++MalignantIncisionalDLBCL++ </td <td>Μ</td> <td>Epithelial</td> <td>Malignant</td> <td>Incisional</td> <td>SCC,</td> <td>+</td> <td>I</td> <td>+</td> <td>I</td> <td>+</td> <td>I</td> <td>+</td> <td>I</td> <td>5</td>	Μ	Epithelial	Malignant	Incisional	SCC,	+	I	+	I	+	I	+	I	5
63MEpithelialMalignantIncisional76FEpithelialMalignantIncisional87MEpithelialMalignantIncisional87MEpithelialMalignantTransnasal61FNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional1tumortumorbiopsy34MNon-epithelialMalignantIncisional1tumortumorbiopsy34MNon-epithelialMalignantIncisional1tumortumorbiopsy	MalignantIncisionalSebaceous+-+-++biopsygland carcinomabiopsygland carcinoma+-+++++MalignantIncisionalSebaceous+-++ <td></td> <td>tumor</td> <td></td> <td>biopsy</td> <td>p16 positive</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		tumor		biopsy	p16 positive									
76Ftumortuposy76FEpithelialMalignantIncisional87MEpithelialMalignantTransnasal87MEpithelialMalignantTransnasal61FNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional10psytumorbiopsybiopsy34MNon-epithelialMalignantIncisional10psytumorbiopsybiopsy	Malignantbiopsy Incisionalgland carcinoma Sebaceous+++MalignantIncisionalSebaceous+-+++MalignantTransnasalMucoepidermoid+MalignantTransnasalMucoepidermoid+MalignantIncisionalBurkitt+-+MalignantIncisionalDLBCL+-+MalignantIncisionalDLBCL+-+MalignantIncisionalDLBCL+-+MalignantIncisionalDLBCL-++-biopsybiopsyDLBCL+++biopsybiopsyDLBCL+++biopsybiopsybiopsybiopsy-+++	Σ	Epithelial	Malignant	Incisional	Sebaceous	+	I	+	I	+	+	I	I	36
87 M Epithelial Malignant Diopsy tumor 87 M Epithelial Malignant Transnasal 61 F Non-epithelial Malignant Incisional 34 M Non-epithelial Malignant Incisional 34 M Non-epithelial Malignant Incisional 34 M Non-epithelial Malignant Incisional 10 tumor biopsy 34 M Non-epithelial Malignant 10 tumor biopsy 10 tumor biopsy	Malignant Transnasal Mucoepidermoid +	ĹŢ	tumor Fnithelial	Malionant	biopsy Incisional	gland carcinoma Sebaceons	+	I	+	+	+	I	I	I	0
87MEpithelialMalignantTransmasal100053tumorbiopsy61FNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional34MNon-epithelialMalignantIncisional10005310005100059100059	Malignant Transnasal Mucoepidermoid +	•	tumor		biopsv	gland carcinoma	-		-	-	-				•
tumor biopsy 6 61 F Non-epithelial Malignant Incisional tumor biopsy 34 M Non-epithelial Malignant Incisional tumor biopsy 34 M Non-epithelial Malignant Incisional tumor biopsy	biopsy carcinona, during DCR low grade Malignant Incisional Burkitt + - + - + - biopsy lymphoma Malignant Incisional DLBCL + - + - + - biopsy DLBCL + - + - + - biopsy DLBCL + - + + - + - biopsy DLBCL + + + +	Μ	Epithelial	Malignant	Transnasal	Mucoepidermoid	+	I	I	I	Ι	I	+	+	12
61 F Non-epithelial Malignant Incisional 34 M Non-epithelial Malignant Incisional 34 M Non-epithelial Malignant Incisional 34 M Non-epithelial Malignant Incisional 1 tumor biopsy 34 M Non-epithelial Malignant Incisional	during DCRlow gradeMalignantIncisionalBurkitt+-+biopsylymphoma+-+-MalignantIncisionalDLBCL+-+-MalignantIncisionalDLBCL+-+-MalignantIncisionalDLBCL+-+-MalignantIncisionalDLBCL+-++biopsybiopsyDLBCL++		tumor		biopsy	carcinoma,									
 34 M Non-epithelial Malignant Incisional biopsy tumor 34 M Non-epithelial Malignant Incisional biopsy tumor 34 M Non-epithelial Malignant Incisional biopsy tumor 	Malignant Incisional DLBCL + - + + - biopsy lymphoma biopsy bubblec + - + - + - biopsy Malignant Incisional DLBCL + - + - + - biopsy Malignant Transnasal DLBCL + + + + biopsy biopsy	ĹŢ	Non-enithelial	Malionant	during DCR Incisional	low grade Burkitt	+	I	+	I	I	I	+	+	¢
 34 M Non-epithelial Malignant Incisional tumor 34 M Non-epithelial Malignant Incisional tumor 	Malignant Incisional DLBCL + - + - + - biopsy DLBCL + - + - + - Malignant Incisional DLBCL + - + - + - biopsy DLBCL + + + + biopsy biopsy	4	tumor		biopsy	lymphoma)
tumor biopsy 34 M Non-epithelial Malignant Incisional tumor biopsy	biopsy biopsy Adignant Incisional DLBCL + - + - + - hiopsy biopsy Malignant Transnasal DLBCL + + + hiopsy biopsy	Μ	Non-epithelial	Malignant	Incisional	DLBCL	+	I	+	I	I	I	+	+	5
tumor biopsy	biopsy – – – – – – – – – – – – – – – – – – –	Μ	tumor Non-epithelial	Malignant	biopsy Incisional	DLBCL	+	I	+	I	I	I	+	I	9
	Maugnant Iransnasal DLBCL – – + + + biopsy	ŗ	tumor		biopsy										
Malignant Iransnasal hionsy		ц	Non-epithelial	Malignant	Iransnasal hionsy	DLBCL	I	I	+	+	+	I	+	I	96

Table I. Continued

	Treatment DCR Period from	s chief complai to diagnosis (months)	- 6	- 11	ا ى	- 5	ا د	ا ک
	Treatment	dacryocystitis	+	I	I	I	+	I
		Diplopia/ Ocular motility disorder	I	I	I	I	I	I
		Pain	I	I	I	I	I	I
	Symptoms	Bloody Mass of Rubefaction Pain Diplopia/ lacri- lacrimal of medial Ocular mation sac canthus motility disorder	I	I	I	Ι	I	+
	SymI	Mass of lacrimal sac	+	+	+	+	+	+
			I	I	I	I	I	I
		Lacri- mation	+	+	I	I	+	+
	Diagnostic Histopathological Mathod Diagnosic	cicolizard	DLBCL	MALT	lymphoma MALT	lymphoma MALT	lymphoma MALT	lymphoma NKT cell lymphoma
	Diagnostic	Man	Incisional	Incisional	biopsy Incisional	biopsy Incisional	biopsy Incisional	biopsy Incisional biopsy
	Benign or	IVI all Bliatt	Malignant	Malignant	Malignant	Malignant	Malignant	Malignant
	Age Sex Epithelial or	tumor	Non-epithelial Malignant	Non-epithelial Malignant	tumor Non-epithelial	tumor Non-epithelial	tumor Non-epithelial	tumor Non-epithelial tumor
tinued	Sex		ц	Μ	Ц	Ц	Μ	Ц
Table II. Continued	Age S	(years)	66	38	56	67	88	69
Table	Pt		20	21	22	23	24	25

m of is

months. Three of the 12 patients had locoregional recurrence, but only one patient with sebaceous adenocarcinoma died of locoregional and brain/bone metastasis. Two patients survived with distant metastatic recurrences (one basaloid SCC and one ACC). Of the non-epithelial tumors, MALT lymphomas were treated with RT alone. Other malignant lymphomas were treated with chemotherapy and/or radiation (*e.g.*, combination chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). No surgery other than a biopsy was performed for malignant lymphoma. The median follow-up was 39.5 (6-171) months, and all patients survived.

Discussion

ACC, Adenoid cystic carcinoma; DCR, dacryocystorhinostomy; DLBCL, diffuse large B-cell lymphoma; MALT lymphoma, mucosa-associated lymphoid tissue lymphoma; N/A, not available; SCC, squamous cell carcinoma.

To date, approximately 800 cases of rare lacrimal sac tumors have been reported (4). The present retrospective study summarized clinical data of 25 such cases treated at the Kyushu University Hospital. Two important concerns related to lacrimal sac tumors are as follows: 1) Most were malignant tumors but difficult to detect, and 2) R0 resection is often difficult because of the proximity of the eye to the tumor lesion and the facial changes that may result from surgical treatment. Therefore, multidisciplinary treatment combining surgery, radiation therapy, and drug therapy is considered necessary. Although a clinical view of lacrimal sac tumors has been proposed, the pathogenesis and effective treatment strategies are uncertain. Our study provides information on lacrimal sac tumors.

Lacrimal gland tumors often include symptoms of chronic dacryocystitis (4). Therefore, cases of dacryocystitis are often misdiagnosed as a tumor when a lacrimal sac biopsy is performed after a long period of chronic dacryocystitis. In our cases, the average time from the symptom onset to the diagnosis was 14.7 months (median=7 months, range=1-96 months), which is extremely long. A large percentage of patients showed epiphora and a history or symptoms of chronic dacryocystitis, such as running tears. However, adherent masses and masses beyond the medial canthal ligament were suspicious findings that should be noted (2, 5). The percentage of cases with a mass above the lacrimal sac upon arrival at our hospital was 90.9%, and such lesions were not detected early. Masses in the lacrimal sac region progress after the diagnosis. Therefore, it is clinically difficult to differentiate from chronic dacryocystitis in the early stage.

Although DCR is commonly performed for chronic dacryocystitis, a neoplastic pathology was found in only 55 of 3,865 (1.42%) cases by a routine lacrimal sac wall biopsy performed at the time of DCR (7). The diagnostic rate of lacrimal sac tumors by a biopsy at the time of DCR is low, and a routine tear sac biopsy with DCR is not recommended unless a tumor is suspected. Therefore, imaging studies, such as magnetic resonance imaging, can help differentiate lacrimal sac tumors from chronic inflammatory diseases (4).

			Sy	mptoms			Treatment history of	DCR
	Lacrimation	Bloody lacrimation	Mass of lacrimal sac	Rubefaction of medial canthus	Pain	Diplopia/Ocular motility disorder	dacryocystitis	
Number of patients	21	3	22	7	7	2	14	5
%	84.0	12.0	88.0	28.0	28.0	8.0	56.0	20.0

Table III. Summary of symptoms and history at initial examination of patients included in the study (n=25).

DCR, Dacryocystorhinostomy.

Our cases had a high rate of malignancy (22/25, 88.0%), similar to previous reports (>55%). Also similar to other studies was the high rate of malignant disease in patients >50 years old, while benign disease tended to occur in the younger age group (4, 5). The pathological diagnosis of benign lacrimal sac tumors has been reported to include squamous cell papilloma, transitional epithelial papilloma, fibrous histiocytoma, and oncocytoma, in that order of frequency (2, 4, 8-10). Furthermore, the pathological diagnosis of malignant lacrimal sac tumors has been reported to include lymphoma, squamous cell carcinoma, melanoma, transitional cell carcinoma, and mucoepidermoid carcinoma, in that order of frequency. Our cases included sebaceous gland carcinomas, which are quite rare.

The main treatment of epithelial tumors is surgery, although the anatomical location of the tumor often does not allow for adequate resection margins. SCC is found in 5.0%-15.8% of cases reported for nasal sinus cancer and often coexists with inverted papilloma (11, 12). Therefore, surgery is determined based on the presence of malignancy (13-15) Medial maxillectomy or extended maxillectomy was required in 11 cases in the present study, including 2 papilloma cases. After resection, 11 cases required free-flap reconstructive surgery. Advances in reconstructive surgery after resection can reduce the risk of postoperative infection and improve the cosmetic appearance. In the current treatment of epithelial malignancies, as head and neck cancer, multidisciplinary treatment, including postoperative (chemo)radiation therapy, is preferred. In 1982, Ni et al. reported a series of 71 patients from Shanghai with lacrimal sac carcinoma; the mortality rate was 43.7% despite orbital exenteration and other radical surgical measures being performed (2, 4, 16). However, recently, epithelial malignancy of the lacrimal sac has been treated with a multidisciplinary approach, as in our institution (3-5). Sawy et al. reported in 2013 that 3 cases of local recurrence in 14 patients were controllable with 100% locoregional control and a median follow-up time of 27 months (3). The overall survival rate for the same period was 79%, which was significantly better than in earlier reports. Multidisciplinary treatment in our 12 cases of epithelial malignancy resulted in good locoregional control (11/12; 91.7%). Distant metastasis occurred in three patients after initial treatment. One of the three patients had TNM recurrence of sebaceous carcinoma 12 months after initial treatment and died

Table IV.	Initial	treatment	for	epithelial	tumors	of	the	lacrimal	sac
(<i>n</i> =15).									

	Treatment	n
Benign	Medial maxillectomy and free-flap	2
	reconstruction surgery	
	Endoscopic sinus surgery	1
Malignant	Medial maxillectomy and free-flap	5
	reconstruction surgery+PO(C)RT	
	Extended total maxillectomy and free-flap	3
	reconstruction surgery+POCRT	
	Medial maxillectomy and free-flap	1
	reconstruction surgery	
	Lateral rhinotomy	1
	Dacryocystectomy+RT	1
	Heavy-ion radiotherapy	1

POCRT, Postoperative chemoradiotherapy; RT, radiotherapy.

36 months after initial treatment. Nivolumab, an ICI, was administered for six months until disease progression, and then paclitaxel was administered to stabilize the disease for nine months. ICIs and subsequent chemotherapy, which have been shown to be effective in other carcinomas, may be effective in treating recurrence and metastasis of lacrimal sac tumors (17, 18). The aforementioned heavy particle therapy has also been reported as a treatment option for advanced local lesions of sinus tumors (19, 20). Although an evidence base for these therapeutic modalities has not yet been established, their advent has led to dramatic changes in treatment approaches.

Another recent topic of interest is human papillomavirus (HPV)-related squamous cell carcinoma. In the field of head and neck squamous cell carcinoma, the characteristics of HPV-infected cases in the oropharynx have attracted much attention over the past decade (21). HPV-related cancers in the nasal cavity have also been reported to have a good response to treatment and a good prognosis (22, 23). Immunostaining results for p16 and Rb, which are surrogate markers for HPV-related cancers, can be combined to determine the presence or absence of HPV-related cancers (24). In the present study, one SCC case was also positive for p16 and Rb partial loss pattern, suggesting it to be an HPV-related cancer. Although this case had intraorbital extension and neck metastases, we assumed

Pts	Pts Age, years	Sex	Histopathological diagnosis		Initial ther	ару		Surgical margin	Recurrence	Observation period	Prognosis
	years		diagnosis	Surgery	Chemotherapy	PORT	POCRT	margin		(months)	
4	45	М	ACC, cribriform subtype	+	_	+	_	Positive	None	13	NED
5	53	М	ACC, cribriform subtype	+	_	+	_	Positive	Local, DM (PUL)	64	AWD
6	57	F	ACC, cribriform subtype	+	-	-	+	Positive	None	30	NED
7	64	F	SCC, p16 (N/A)	+	_	+	_	N/A	DM (HEP)	86	AWD
8	58	F	SCC, p16 (N/A)	+	_	_	_	Negative	None	19	NED
9	61	F	SCC, p16 (N/A)	+	_	_	+	Positive	None	176	NED
10	57	Μ	SCC, p16 negative	+	_	_	_	Negative	None	39	NED
11	70	Μ	SCC, p16 positive	+	_	_	+	Positive	None	50	NED
12	48	М	SCC, p16 positive, Rb partial loss	+	-	-	+	Positive	None	17	NED
13	63	М	Sebaceous gland carcinoma	+	_	_	+	Positive	Local, Regional lymph node, DM (OSS, BRA	36	DOD
14	76	F	Sebaceous gland carcinoma	Heavy-ion radiotherap		-	-	N/A	Regional lymph node	48	NED
15	87	М	Mucoepidermoid carcinoma	+	_	-	-	Negative	None	31	NED

Table V. Summary of treatment and prognosis of epithelial malignancy of the lacrimal sac (n=12).

ACC, Adenoid cystic carcinoma; AWD, alive with disease; BRA, brain metastasis; DM, distant metastasis; DOD, dead of disease; HEP, liver metastasis; NED, no evidence of disease; OSS, bone metastasis; PUL, pulmonary metastasis; SCC, squamous cell carcinoma.

that it would respond to treatment as well as oropharyngeal and sinonasal cancers. With chemoradiotherapy (CRT) after eye-sparing surgery with neck dissection, the patient has been free from recurrence for 17 months since the treatment. In the future, there may be room to consider less-intense treatment or CRT alone for HPV-related squamous cell carcinoma of the lacrimal canal. The treatment strategy for malignant lacrimal sac tumors should be updated, which will require the accumulation of more case reports.

Several limitations associated with the present retrospective study warrant mentioning. Due to the small number of cases, variability of pathological diagnoses, and short follow-up period, caution should be practiced before applying these treatment approaches directly to clinical practice.

We reported our experience in treating lacrimal sac tumors at our Institution. At the time of initial diagnosis, a mass in the lacrimal sac region was observed in most cases, so subjective symptoms of lacrimal sac tumors may prove useful. Malignant tumors require multidisciplinary treatment, that was performed in our case, achieving good local control. In order to treat tumors in the fields of ophthalmology, head and neck surgery, plastic surgery, radiology, and oncology, cooperation among specialists in these fields is necessary. Postoperative radiotherapy as a local treatment may be useful. New options for making diagnoses and performing treatment are being introduced, and we need to take advantage of these advances to improve the patient prognosis. For this reason, we need to continue to examine these cases to help guide future treatment strategies.

Conflicts of Interest

The Authors declare no conflicts of interest in relation to this study.

Authors' Contributions

Conceptualization, T.W.; Methodology, T.W. and R.Y.; Validation, T.W.; Investigation, T.W., M.T., H.T., R.J., K.H., M.M., and K.H.; Writing – Original Draft Preparation, T.W.; Writing – Review & Editing, R.Y., M.T. and A.F.; Supervision, H.Y. and T.N.; Project Administration, R.Y.; Funding Acquisition, T.W. All Authors have read and agreed to the published version of the manuscript.

Acknowledgements

The study was supported by a grant from JSPS KAKENHI Grant Number JP 20K09716 to Takahiro Wakasaki. We would like to thank Japan Medical Communication for the English language editing.

References

- 1 Cochran ML, Aslam S and Czyz CN: Anatomy, head and neck, eye nasolacrimal. Treasure Island, FL, USA, StatPearls Publishing, 2020.
- 2 Ni C, D'Amico DJ, Fan CQ and Kuo PK: Tumors of the lacrimal sac: a clinicopathological analysis of 82 cases. Int Ophthalmol Clin 22(1): 121-140, 1982. PMID: 6277817. DOI: 10.1097/00004397-198202210-00010
- 3 El-Sawy T, Frank SJ, Hanna E, Sniegowski M, Lai SY, Nasser QJ, Myers J and Esmaeli B: Multidisciplinary management of lacrimal sac/nasolacrimal duct carcinomas. Ophthalmic Plast

Reconstr Surg 29(6): 454-457, 2013. PMID: 24195987. DOI: 10.1097/IOP.0b013e31829f3a73

- 4 Krishna Y and Coupland SE: Lacrimal sac tumors—a review. Asia Pac J Ophthalmol (Phila) 6(2): 173-178, 2017. PMID: 28399337. DOI: 10.22608/APO.201713
- 5 Song X, Wang J, Wang S, Wang W, Wang S and Zhu W: Clinical analysis of 90 cases of malignant lacrimal sac tumor. Graefes Arch Clin Exp Ophthalmol 256(7): 1333-1338, 2018. PMID: 29707735. DOI: 10.1007/s00417-018-3962-4
- 6 Sjö LD, Ralfkiaer E, Juhl BR, Prause JU, Kivelä T, Auw-Haedrich C, Bacin F, Carrera M, Coupland SE, Delbosc B, Ducrey N, Kantelip B, Kemeny JL, Meyer P, Sjö NC, Heegaard S and European Organization for Research and Treatment of Cancer: Primary lymphoma of the lacrimal sac: an EORTC ophthalmic oncology task force study. Br J Ophthalmol *90(8)*: 1004-1009, 2006. PMID: 16672329. DOI: 10.1136/bjo.2006.090589
- 7 Koturović Z, Knežević M and Rašić DM: Clinical significance of routine lacrimal sac biopsy during dacryocystorhinostomy: A comprehensive review of literature. Bosn J Basic Med Sci 17(1): 1-8, 2017. PMID: 27754826. DOI: 10.17305/bjbms.2016.1424
- 8 Elner VM, Burnstine MA, Goodman ML and Dortzbach RK: Inverted papillomas that invade the orbit. Arch Ophthalmol *113(9)*: 1178-1183, 1995. PMID: 7661753. DOI: 10.1001/ archopht.1995.01100090104030
- 9 Madreperla SA, Green WR, Daniel R and Shah KV: Human papillomavirus in primary epithelial tumors of the lacrimal sac. Ophthalmology 100(4): 569-573, 1993. PMID: 8386822. DOI: 10.1016/s0161-6420(93)31629-5
- 10 Sjö NC, von Buchwald C, Cassonnet P, Flamant P, Heegaard S, Norrild B, Prause JU and Orth G: Human papillomavirus: cause of epithelial lacrimal sac neoplasia? Acta Ophthalmol Scand 85(5): 551-556, 2007. PMID: 17362365. DOI: 10.1111/j.1600-0420.2007.00893.x
- 11 Gustafson C, Einhorn E, Scanlon MH, Morgenstern KE, Howlett PJ and Cohen NA: Synchronous verrucous carcinoma and inverted papilloma of the lacrimal sac: case report and clinical update. Ear Nose Throat J 92(10-11): E1, 2013. PMID: 24170467.
- 12 Yasumatsu R, Nakashima T, Sato M, Nakano T, Kogo R, Hashimoto K, Sawatsubashi M and Nakagawa T: Clinical management of squamous cell carcinoma associated with sinonasal inverted papilloma. Auris Nasus Larynx 44(1): 98-103, 2017. PMID: 27108101. DOI: 10.1016/j.anl.2016.04.004
- 13 Afrogheh AH, Jakobiec FA, Hammon R, Grossniklaus HE, Rocco J, Lindeman NI, Sadow PM and Faquin WC: Evaluation for high-risk HPV in squamous cell carcinomas and precursor lesions arising in the conjunctiva and lacrimal sac. Am J Surg Pathol 40(4): 519-528, 2016. PMID: 26735858. DOI: 10.1097/ PAS.000000000000581
- 14 Furdová A, Stopková A, Kapitánová K, Kobzová D and Babál P: Conjuctival lesions - the relationship of papillomas and squamous cell carcinoma to HPV infection. Cesk Slov Oftalmol 74(3): 92-97, 2018. PMID: 30650971. DOI: 10.31348/2018/1/2-3-2018
- 15 Wang J, Ford J, Esmaeli B, Langer P, Esmaili N, Griepentrog GJ, Couch SM, Nguyen J, Gold KG, Duerksen K, Burkat CN, Hartstein ME, Gandhi P, Sobel RK, Moon JY and Barmettler A: Inverted papilloma of the orbit and nasolacrimal system. Ophthalmic Plast Reconstr Surg 37(2): 161-167, 2021. PMID: 32501879. DOI: 10.1097/IOP.000000000001719
- 16 Kanyinda N, Soni S, Ramadan A and Kidwell E: Complete resolution of a large squamous cell carcinoma of the lacrimal

duct in a young African American male after non-surgical management. Am J Ophthalmol Case Rep *19*: 100842, 2020. PMID: 32775768. DOI: 10.1016/j.ajoc.2020.100842

- 17 Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW and Gillison ML: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19): 1856-1867, 2016. PMID: 27718784. DOI: 10.1056/NEJMoa1602252
- 18 Wakasaki T, Yasumatsu R, Uchi R, Taura M, Matsuo M, Komune N and Nakagawa T: Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. Auris Nasus Larynx 47(1): 116-122, 2020. PMID: 31128940. DOI: 10.1016/j.anl.2019.05.001
- 19 Toyomasu Y, Demizu Y, Matsuo Y, Sulaiman NS, Mima M, Nagano F, Terashima K, Tokumaru S, Hayakawa T, Daimon T, Fuwa N, Sakuma H, Nomoto Y and Okimoto T: Outcomes of patients with sinonasal squamous cell carcinoma treated with particle therapy using protons or carbon ions. Int J Radiat Oncol Biol Phys 101(5): 1096-1103, 2018. PMID: 29859787. DOI: 10.1016/j.ijrobp.2018.04.041
- 20 Hu W, Hu J, Huang Q, Gao J, Yang J, Qiu X, Kong L and Lu JJ: Particle beam radiation therapy for adenoid cystic carcinoma of the nasal cavity and paranasal sinuses. Front Oncol *10*: 572493, 2020. PMID: 33102230. DOI: 10.3389/fonc.2020. 572493
- 21 Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP and Gillison ML: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1): 24-35, 2010. PMID: 20530316. DOI: 10.1056/NEJMoa0912217
- 22 Jiromaru R, Yamamoto H, Yasumatsu R, Hongo T, Nozaki Y, Hashimoto K, Taguchi K, Masuda M, Nakagawa T and Oda Y: HPV-related sinonasal carcinoma: Clinicopathologic features, diagnostic utility of p16 and Rb immunohistochemistry, and EGFR copy number alteration. Am J Surg Pathol 44(3): 305-315, 2020. PMID: 31743130. DOI: 10.1097/PAS. 000000000001410
- 23 Jiromaru R, Yasumatsu R, Yamamoto H, Kuga R, Hongo T, Nakano T, Manako T, Hashimoto K, Wakasaki T, Matsuo M and Nakagawa T: A clinical analysis of oropharyngeal squamous cell carcinoma: a single-institution's experience. Eur Arch Otorhinolaryngol 279(7): 3717-3725, 2022. PMID: 34978590. DOI: 10.1007/s00405-021-07236-z
- 24 Jiromaru R, Yamamoto H, Yasumatsu R, Hongo T, Nozaki Y, Nakano T, Hashimoto K, Nakagawa T and Oda Y: p16 overexpression and Rb loss correlate with high-risk HPV infection in oropharyngeal squamous cell carcinoma. Histopathology 79(3): 358-369, 2021. PMID: 33450095. DOI: 10.1111/his.14337

Received January 31, 2023 Revised February 24, 2023 Accepted March 6, 2023